Advertisement
Canada markets close in 4 hours 20 minutes

  • S&P/TSX

    21,803.47
    -70.25 (-0.32%)
     

  • S&P 500

    5,011.48
    -60.15 (-1.19%)
     

  • DOW

    37,870.40
    -590.52 (-1.54%)
     

  • CAD/USD

    0.7302
    +0.0004 (+0.06%)
     

  • CRUDE OIL

    82.25
    -0.56 (-0.68%)
     

  • Bitcoin CAD

    87,461.10
    -1,352.78 (-1.52%)
     

  • CMC Crypto 200

    1,375.39
    -7.19 (-0.52%)
     

  • GOLD FUTURES

    2,345.30
    +6.90 (+0.30%)
     

  • RUSSELL 2000

    1,967.19
    -28.24 (-1.41%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ

    15,456.08
    -256.67 (-1.63%)
     

  • VOLATILITY

    16.91
    +0.94 (+5.90%)
     

  • FTSE

    8,075.82
    +35.44 (+0.44%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • CAD/EUR

    0.6810
    -0.0009 (-0.13%)
     
BREAKING:

HONDA TO SET UP $15B EV PRODUCTION BASE IN CANADA

Automaker to get up to $5B in government assistance for EV battery, assembly plants

Certara to Report First Quarter 2022 Financial Results on May 5th, 2022

Certara USA, Inc.
·1 min read
Certara USA, Inc.
Certara USA, Inc.

PRINCETON, N.J., April 20, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of 2022 after the market close on Thursday, May 5th, 2022. Company management will host a conference call to discuss financial results at 5:00 p.m. ET.

Investors interested in listening to the conference call may do so by dialing (833) 360-0946 for domestic callers or (914) 987-7661 for international callers, followed by Conference ID: 1290087. A live and archived webcast of the event will be available on the “Investors” section of the Certara website at https://ir.certara.com/.

About Certara
Certara accelerates medicines using proprietary biosimulation software, technology and services to transform traditional drug discovery and development. Its clients include more than 2,000 biopharmaceutical companies, academic institutions and regulatory agencies across 62 countries. Visit us at www.certara.com.

Investor Relations Contact:
David Deuchler
Gilmartin Group
ir@certara.com

Media Contact:
Daniel Yunger
Kekst CNC
daniel.yunger@kekstcnc.com